問卷

TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Digestive System Department

Division of Radiology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Surgery

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

陳彥豪
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

261Cases

2025-12-01 - 2033-05-05

Phase III

Not yet recruiting
FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration
  • Condition/Disease

    Carcinoma, Transitional Cell、 Urinary Bladder Neoplasms 、Neoplasm Metastasis

  • Test Drug

    N/A

Participate Sites
10Sites

Recruiting5Sites

2020-01-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-05-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-12-01 - 2027-12-31

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-02-01 - 2025-12-10

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2016-06-01 - 2024-06-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-09-01 - 2027-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2020-09-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-10-01 - 2035-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2012-11-30 - 2017-06-30

Phase IV

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites